2 ms·
Thanks for the correction. I thought Phase I was a pre-human clinical trial for safety, rather than a human clinical trial. I appear to have been mistaken.
by jcranmer 8y ago
Thanks for the correction. I thought Phase I was a pre-human clinical trial for safety, rather than a human clinical trial. I appear to have been mistaken.
- gumby 8y agoNo problem. Preclinical work is indeed called preclinical work :-). Typically you do a bunch of in vitro and in vivo studies when developing your drug candidate. When you're ready to file the IND (asking permission to test on humans) you do a different set of studies specifically to generate the data you need for your submission. Sometimes the agency will even tell you where its concerns may lie so you might use a specific animal or specific test to address them. You also include a lot of in vitro work about how you manufacture (and control the mfg of) your test product. The difference might be that you take and process a lot of samples in your R&D stage, and then when you prepare your submission you get independent labs to do the work (to show the agency you don't have your "finger on the pan" so to speak). For example on a depot-injectable drug I worked on we did six experiment sites per guinea pig (because we knew tissue diffusion would be only a few millimeters) which saved us time and a lot of money but when preparing for the FDA we did only one per, so we could guarantee to them that any trace of drug found anywhere in the tissue came from a single injection. Likewise we did a lot of pathology ourselves just peering through the microscope (and learned a lot!), but for the FDA we had the animal lab send tissue samples directly to an external pathologist who then sent us a report without any input from us. Etc.